Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
28 11 2022
Historique:
received: 10 12 2021
accepted: 04 03 2022
pubmed: 15 3 2022
medline: 2 12 2022
entrez: 14 3 2022
Statut: ppublish

Résumé

MCTD manifests with microvasculopathy and overlapping clinical features of SLE, SSc and idiopathic inflammatory myopathies (IIM). The aim of this study was to investigate the clinical significance of microvasculopathy in patients with MCTD using nailfold videocapillaroscopy (NVC). Fifty patients with newly diagnosed and untreated MCTD were enrolled in this multicentre, prospective and observational study. Clinical features and NVC findings were assessed at baseline and after 1 year post-intervention, along with disease controls [SLE (n = 40), SSc (n = 70) and IIM (n = 50)]. All MCTD patients presented Raynaud's phenomenon and were positive for anti-U1 RNP antibodies, and 22.0% (11/50) had pulmonary arterial hypertension (PAH). The prevalence of NVC scleroderma patterns in MCTD was 38.0%, which was lower than SSc (88.6%) but higher than SLE (10.0%). In addition, when we divided MCTD patients into two groups by presence or absence of NVC scleroderma patterns, we found a higher prevalence of PAH in patients with NVC scleroderma patterns. Namely, NVC scleroderma patterns were observed in all MCTD patients with PAH, and in 21.0% of those without PAH. After intensive immunosuppressive therapy, NVC scleroderma patterns disappeared in half of the MCTD patients but were not changed in SSc patients. MCTD differed from SLE, SSc and IIM in terms of the prevalence and responsiveness of NVC scleroderma patterns to immunosuppressive therapy. Detection of nailfold microvascular abnormalities in MCTD could contribute to predicting PAH and help us to understand further aspects of the pathogenesis of MCTD.

Identifiants

pubmed: 35285493
pii: 6548159
doi: 10.1093/rheumatology/keac165
doi:

Types de publication

Observational Study Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4875-4884

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Yasuyuki Todoroki (Y)

First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Satoshi Kubo (S)

First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Kazuhisa Nakano (K)

First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Yusuke Miyazaki (Y)

First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Masanobu Ueno (M)

First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Yurie Satoh-Kanda (Y)

Department of Internal Medicine, Kitakyushu General Hospital, Kitakyushu, Japan.

Ryuichiro Kanda (R)

Department of Internal Medicine, Kitakyushu General Hospital, Kitakyushu, Japan.

Ippei Miyagawa (I)

First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Kentaro Hanami (K)

Wakamatsu Hospital of the University of Occupational and Environmental Health, Kitakyushu.

Keisuke Nakatsuka (K)

Department of Internal Medicine, Fukuoka Yutaka Central Hospital, Fukuoka.

Kazuyoshi Saito (K)

Department of Internal Medicine, Tobata General Hospital, Kitakyushu, Japan.

Shingo Nakayamada (S)

First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Yoshiya Tanaka (Y)

First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH